H.C. Wainwright says acquisitions in the radiopharma sector, including AstraZeneca’s (AZN) deal today to buy its partner in radiopharmaceuticals, Fusion Pharma (FUSN), for an upfront value of $2.0B in cash underscores Actinium Pharmaceuticals’ (ATNM) potential and business development prospects. A deal of this size underscores the continued interest in the radiopharmaceutical space as a whole, says the analyst, who sees a positive read-through for Actinium in particular. Actinium is well positioned “for a similar takeout route,” contends H.C. Wainwright. The firm has a Buy rating on the shares with a $50 price target. The stock in morning trading is up 20% to $7.86.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>